Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
J. Cadranel (Paris, France). TKIs: a new class of drugs in the management of lung cancer. Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Precision medicine for lung cancer: new targeted treatments  Source: International Congress 2017 – Precision medicine approaches in lung cancer Year: 2017 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 New chemotherapeutic agents Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259 Year: 2001 Immunology-based therapeutic strategies in lung cancer and mesothelioma Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology Year: 2014 New and anticipated therapeutic developments in management of non-small-cell lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 New and emerging targeted treatments in advanced lung cancer Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Innovative local therapies in lung cancer Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010